Rebecca Haynes, NP
Psychiatric/Mental Health · Fort Wayne, INNPI 1326577354
Payments from drug & device makers
Across 217 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$992
- AbbVie$590
- Otsuka America Pharmaceutical, Inc.$499
- E.r. Squibb & Sons, L.L.C.$301
- Alkermes, Inc.$263
- Lundbeck LLC$213
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,83097%
- Education$1113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 48 | $992 |
| AbbVie | 56 | $590 |
| Otsuka America Pharmaceutical, Inc. | 21 | $499 |
| E.r. Squibb & Sons, L.L.C. | 16 | $301 |
| Alkermes, Inc. | 11 | $263 |
| Lundbeck LLC | 12 | $213 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $198 |
| Supernus Pharmaceuticals, Inc. | 8 | $171 |
| Teva Pharmaceuticals USA, Inc. | 4 | $142 |
| Neurocrine Biosciences, Inc. | 5 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $72 |
| Biogen | 3 | $69 |
| Indivior Inc. | 4 | $64 |
| Merck | 4 | $59 |
| Johnson & Johnson | 3 | $55 |
| Ironshore Pharmaceuticals Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Corium, LLC | 3 | $39 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$102
How this compares
$3,942 in reported general payments places this provider in the 85th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 52 | $451,082 |
| IngrezzaValbenazine Tosylate | 53 | $438,565 |
| Invega SustennaPaliperidone Palmitate | 122 | $409,570 |
| VraylarCariprazine Hcl | 177 | $252,879 |
| RexultiBrexpiprazole | 140 | $225,865 |
| Abilify MaintenaAripiprazole | 81 | $220,301 |
| Invega TrinzaPaliperidone Palmitate | 16 | $148,282 |
| Austedo XrDeutetrabenazine | 12 | $76,523 |
| AristadaAripiprazole Lauroxil | 14 | $57,427 |
| CaplytaLumateperone Tosylate | 18 | $38,721 |
| TrintellixVortioxetine Hydrobromide | 56 | $37,208 |
| Aripiprazole | 238 | $33,850 |
| Risperdal ConstaRisperidone Microspheres | 26 | $32,579 |
| ClozarilClozapine | 16 | $21,096 |
| BelsomraSuvorexant | 33 | $19,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $55 | $590,432164 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $142 | $527,60564 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $499 | $446,166221 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $88 | $438,56553 claims |
| AbbVieVraylar | $590 | $252,879177 claims |
| Alkermes, Inc.Aristada | $263 | $57,42714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $72 | $43,87073 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $198 | $38,72118 claims |
| MerckBelsomra | $59 | $19,32733 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $41 | $14,48713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Fort Wayne
- Sharon ClevengerFort Wayne$22K
- Teresa RobertsFort Wayne$13K
- Melodie GavinFort Wayne$9K
- Valerie RumpleFort Wayne$8K
- Sherri AlbertsonFort Wayne$6K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.